Nelson Hamerschlak

Nelson Hamerschlak

Hospital Israelita Albert Einstein - São Paulo / Brazil
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4616241
Albert Einstein Israeli Hospital
person_outline Nelson Hamerschlak's MOST POPULAR ARTICLES
1-) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisisJ Cortes, P Rousselot, DW Kim, E Ritchie, N Hamerschlak, S Coutre, ...Blood 109 (8), 3207-3213, 20075482007
2-) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialH Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ...Blood, The Journal of the American Society of Hematology 109 (12), 5143-5150, 20075312007
3-) Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two‐year follow‐up of a randomized …H Kantarjian, R Pasquini, V Lévy, S Jootar, J Holowiecki, N Hamerschlak, ...Cancer: Interdisciplinary International Journal of the American Cancer …, 20092892009
4-) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosisPA Muraro, M Pasquini, HL Atkins, JD Bowen, D Farge, A Fassas, ...JAMA neurology 74 (4), 459-469, 20172892017
5-) Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phaseJ Cortes, DW Kim, E Raffoux, G Martinelli, E Ritchie, L Roy, S Coutre, ...Leukemia 22 (12), 2176-2183, 20082592008